DergiPark (Istanbul University)· 2019
The Effect of Dexamethasone Treatment on Maternal Outcome in HELLP Syndrome
- 0citations
- 2019year
Short summary
Dexamethasone treatment did not significantly improve maternal outcomes in HELLP syndrome patients, showing no difference in ICU stay, transfusion needs, or mortality compared to untreated patients (n=20).
AI-generated from the title and abstract; the full text is not read.
Key points
- Dexamethasone treatment did not significantly alter mortality rates in HELLP syndrome patients.
- Intensive care unit (ICU) length of stay was not significantly different between dexamethasone-treated and untreated HELLP syndrome patients.
- Transfusion requirements were similar for patients who received dexamethasone and those who did not.
- While platelet counts tended to increase more in the dexamethasone group, the difference was not statistically significant.
AI-generated from the title and abstract; the full text is not read.
Abstract
Amac: HELLP (Hemolysis, elevated liver enzymes, and low platelets) sendromu gebeligin ciddi komplikasyonlarindan birisidir. Literaturde HELLP sendromunun tedavisinde kortikosteroid kullanimi ile ilgili celiskili bilgiler bulunmaktadir. Bu calismanin amaci deksametazon tedavisinin maternal sonuclar uzerindeki etkisinin arastirilmasidir. Yontemler: Calismaya HELLP sendromu tanisi ile yogun bakim unitesinde izlenen 20 hasta dahil edilmistir. Hasta yasi, gestasyonel yas, Mississipi sinflandirmasi, APACHE II skoru, hematolojik ve biyokimyasal olcumler, mortalite ve yogun bakim yatis gunu gibi parametreler analiz edilmistir. Bulgular: Hastalardan ikisi coklu organ yetmezligine bagli olarak olmustur. Iki intrauterine ve bir premature bebek olumu gerceklesmistir. On iki hastaya deksametazon tedavisi verilmis (Grup 1), 8 hasta ise kortikosteroid tedavisi almamistir. Gruplar arasinda yogun bakim yatis suresi, transfuzyon gereksinimi ve mortalite acisindan anamli fark saptanmamistir. Deksametazon tedavisi verilen grupta trombosit sayilarinda artis daha fazla gerceklesmistir ancak bu artis istatistiksel fark yaratacak duzeyde olmamistir. Sonuc: HELLP sendromu tedavisinde dekzametazon kullanimi mortalite, yogun bakim yatis gunu ve trombosit sayilarinda anlamli bir fark yaratmamaktadir.
The authors' abstract, as published at the source. DergiPark (Istanbul University), 2019 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Obstetrics and Gynecology
Obstetrics and GynecologyMedicine